S*Bio Preliminary Clinical Data Presented at the 20th EORTC-NCI-ACR Symposium on 'Molecular Targets and Cancer Therapeutics'
22 Oct 2008
Orphan DrugSmall molecular drugAACR
SINGAPORE, Oct. 22 /PRNewswire/ -- S*BIO Pte Ltd today announced that multiple presentations of pre-clinical and early clinical data for its HDAC inhibitor SB939HDAC inhibitor SB939 will be made at the 20th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics" in Geneva, Switzerland. The results demonstrate that the "best-in-class" pre-clinical pro S*BIO's novel anti-cancer drug SB939 translates into the clinic.
"We are pleased to announce clinical data from the ongoing Phase 1 trials of our orally-active HDAC inhibitor SB939HDAC inhibitor SB939," said Dr. Jan-Anders Karlsson, CEO of S*BIO. "The pharmacokinetic and pharmacodynamic data obtained with SB939 in patients with advanced cancers are consistent with the superior HDAC inhibitor proHDAC inhibitor pro we have previously demonstrated in pre-clinical studies."
"We continue to develop SB939 in the clinic to gain additional data on its anti-cancer activity as well as to demonstrate further its good tolerability and superior oral PK/PD profile."
Poster No. 136
Discovery of SB939, an HDAC inhibitor with a superior pre-clinical pro >
SB939 is a potent HDAC inhibitor with superior anti-tumor efficacy and tolerability in pharmacological cancer models. The drug candidate also has favourable ADME, safety and pharmaceutical properties resulting in high and dose-proportional exposure after oral dosing. SB939 has a prolonged duration of action and is enriched in tumor tissue which may contribute to its potent anti-tumor activity and "best-in-class" profile. The structure-activity relationships leading to the discovery of SB939 will be discussed.
Poster No. 83
A robust and quantitative biomarker assay for SB939, a potent, orally-active HDACHDAC inhibitor
A robust, sensitive and quantitative Western blot assay for measuring acetylated histone 3 in tissues has been developed to evaluate the target efficacy of SB939 and is currently being used to study PK/PD relationships in the ongoing Phase 1 clinical trials. These data demonstrate that the excellent PK/PD relationship observed in pre-clinical models is mirrored in patients with advanced solid malignancies.
Poster No. 413
A Phase 1 dose escalation study of oral SB939 when administered thrice weekly (every other day) for 3 weeks in a 4-week cycle in patients with advanced solid malignancies
SB939 shows excellent linear and dose-dependent oral exposure. It has a good PK/PD relationship, as well as promising clinical activity with a manageable toxicity profile. The recommended Phase 2 dose has been selected.
About S*BIO Pte Ltd
S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. Its second compound, SB1518, commenced Phase1 clinical trials in 2008 and has received orphan drug designation from the U.S. FDA. A third compound, SB1317, is in pre-clinical development.
In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include Bio*One Capital, Aravis Venture, Novartis Bioventures and other international funds. More information about S*BIO can be found at
CONTACT: Stephen Keith Rhind, Senior Vice President, Corporate Development
Ph.D. of S*BIO Pte Ltd, Tel: +65 6827 5000 (Singapore), or
Stephen_rhind@sbio.com; Tony Russo, +1-212-845-4251, or
Tony.Russo@russopartnersllc.com, or Andreas Marathovouniotis,
+1-212-845-4235, or Andreas.Marathis@russopartnersllc.com, both of Russo
Partners
Web site:
Organizations
Indications
Targets
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.